Reviewer's report

Title: Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis

Version: 0 Date: 03 Aug 2015

Reviewer: Takashi Nomiyama

Reviewer's report:

Dear Authors, I would like to thank you for submitting your manuscript entitled "Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis" to BMC Endocrine Disorders. In the present study, authors tried to investigate efficacy and safety of SGLT2 inhibitor canagliflozin in a "real world" treatment of type 2 diabetes. This kind of study may obtain important clinical information different from phase III clinical trials. However, this manuscript has criticisms and is not good enough for publication.

Major

1. The biggest problem is subjects' number. In table 1, total patients was 4,017. However, patients whose baseline and follow-up HbA1c were measured and compared was only 826. Where is another 3,191 patients? They dropped out? If only 829 patients could be followed-up, table 1 should be changed and study scale should be reduced.

2. Any adverse effects was not described. Authors should show adverse effects of canagliflozin in a real world.

3. How DSCI complications was changed after 6 months treatment by canagliflozin?

4. I would like to know HbA1c reduction volume depending on concomitant AHA, instead of Figure 3.

Are the methods appropriate and well described? If not, please specify what is required in your comments to the authors.

No

Does the work include the necessary controls? If not, please specify which controls are required in your comments to the authors.

No
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I recommend additional statistical review

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

None

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons
CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal